FibriCheck - founded in 2014 - pioneers cardiovascular health solutions, redefining commercial devices as medical instruments through its software-as-a-medical-device approach. With over 1,2M users and the trust of thousands of physicians and multiple insurance providers, FibriCheck has amassed 40 million monitoring days, reshaping disease management through 30 customisable cardiovascular pathways (including targeted prevention, palpitation management and post-diagnosis monitoring)
Central to its innovation is a proprietary AI platform seamlessly processing optical data obtained from any smartphone camera and optical wearable sensor. Refined over the last years, the arrhythmia module detects 14 types of arrhythmias with precision, validated by 85+ peer-reviewed publications.
FibriCheck is very versatile and offers standalone and integrated solutions addressing the entire patient life cycle. Globally impactful, we secured market access in Australia(TGA), Europe (CE-Class IIa), Hong Kong, Saudi Arabia (SFDA), Singapore, UK (MHRA) and the US (FDA) emerging as a transformative force against cardiovascular diseases.
Life Science, Healthcare & Cosmetics
Product
Converting consumer devices into regulated medical tools to combat cardiac diseases
FibriCheck is a device-agnostic AI platform, converting consumer devices into regulated medical tools to combat cardiac diseases.